Literature DB >> 16424019

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Deepti B Ramnarain1, Seongmi Park, Diana Y Lee, Kimmo J Hatanpaa, Shane O Scoggin, Hasan Otu, Towia A Libermann, Jack M Raisanen, Raheela Ashfaq, Eric T Wong, Julian Wu, Robert Elliott, Amyn A Habib.   

Abstract

The epidermal growth factor receptor (EGFR) gene is commonly amplified and rearranged in glioblastoma multiforme leading to overexpression of wild-type and mutant EGFRs. Expression of wild-type EGFR ligands, such as transforming growth factor-alpha (TGF-alpha) or heparin-binding EGF (HB-EGF), is also often increased in gliomas resulting in an autocrine loop that contributes to the growth autonomy of glioma cells. Glioblastoma multiformes express a characteristic EGFR mutant (EGFRvIII, de 2-7) that does not bind ligand, signals constitutively, and is more tumorigenic than the wild-type receptor. However, the downstream signals that mediate this increased tumorigenicity are not well understood. We hypothesized that signals induced specifically by EGFRvIII and not the wild-type receptor are more likely to mediate its increased tumorigenic activity and examined the gene expression profiles resulting from inducible expression of comparable levels of either wild-type EGFR or EGFRvIII in a U251-MG glioma cell line. Expression of EGFRvIII resulted in specific up-regulation of a small group of genes. Remarkably, all these genes, which include TGFA, HB-EGF, EPHA2, IL8, MAP4K4, FOSL1, EMP1, and DUSP6, influence signaling pathways known to play a key role in oncogenesis and function in interconnected networks. Increased expression of EGFRvIII-induced genes was validated by real-time PCR. The mutant receptor does not bind ligand, and EGFRvIII-induced expression of TGF-alpha and HB-EGF suggests that EGFRvIII plays a role in generating an autocrine loop using the wild-type EGFR in glioma. It also raises the possibility that EGFRvIII may signal, at least in part, through the wild-type receptor. Indeed, we show that inhibiting the activity of HB-EGF, a potent mitogen, with neutralizing antibodies reduces cell proliferation induced by expression of EGFRvIII. This suggests that the EGFRvIII-HB-EGF-wild-type EGFR autocrine loop plays an important role in signal transduction by EGFRvIII in glioma cells. We also show by immunohistochemistry that HB-EGF expression correlates with the presence of EGFRvIII in glioblastoma multiforme. Thus, our study provides a new insight into oncogenic signaling by EGFRvIII and improves our understanding of how autocrine loops are generated in glioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424019     DOI: 10.1158/0008-5472.CAN-05-2753

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

1.  Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.

Authors:  Hannah O'Farrell; Bryant Harbourne; Zimple Kurlawala; Yusuke Inoue; Amy L Nagelberg; Victor D Martinez; Daniel Lu; Min Hee Oh; Bradley P Coe; Kelsie L Thu; Romel Somwar; Stephen Lam; Wan L Lam; Arun M Unni; Levi Beverly; William W Lockwood
Journal:  J Thorac Oncol       Date:  2018-12-19       Impact factor: 15.609

Review 2.  Map4k4 Signaling Nodes in Metabolic and Cardiovascular Diseases.

Authors:  Joseph V Virbasius; Michael P Czech
Journal:  Trends Endocrinol Metab       Date:  2016-05-06       Impact factor: 12.015

3.  EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism.

Authors:  G Pines; P H Huang; Y Zwang; F M White; Y Yarden
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

4.  Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Authors:  Jaime Acquaviva; Hyun Jung Jun; Julie Lessard; Rolando Ruiz; Haihao Zhu; Melissa Donovan; Steve Woolfenden; Abraham Boskovitz; Ami Raval; Roderick T Bronson; Rolf Pfannl; Charles A Whittaker; David E Housman; Al Charest
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

5.  The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas.

Authors:  Stephan Dützmann; Florian Gessler; Patrick N Harter; Rüdiger Gerlach; Michel Mittelbronn; Volker Seifert; Donat Kögel
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

Review 6.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

7.  Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.

Authors:  Mark Katakowski; Feng Jiang; XuGuang Zheng; Jorge A Gutierrez; Alexandra Szalad; Michael Chopp
Journal:  Cancer Sci       Date:  2009-05-18       Impact factor: 6.716

Review 8.  Ligand-Independent EGFR Signaling.

Authors:  Gao Guo; Ke Gong; Bryan Wohlfeld; Kimmo J Hatanpaa; Dawen Zhao; Amyn A Habib
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

9.  Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens.

Authors:  Sergio Comincini; Mayra Paolillo; Giulia Barbieri; Silvia Palumbo; Elena Sbalchiero; Alberto Azzalin; Marika A Russo; Sergio Schinelli
Journal:  J Biomed Biotechnol       Date:  2009-07-30

10.  Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion.

Authors:  Xuguang Zheng; Feng Jiang; Mark Katakowski; Xuepeng Zhang; Hao Jiang; Zheng Gang Zhang; Michael Chopp
Journal:  Cancer Lett       Date:  2008-03-20       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.